# Biobytes

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biobytes

- Industry: Healthcare
- Headquarters: Chuncheon-si, South Korea
- Website: https://biobytes.kr/en
- Total disclosed funding: $0.4M
- Latest round: Seed (Nov 20, 2024)
- Investors on record: 4

## About

Based in Gangwon-do, South Korea, founded in 2023, BioBytes Co., Ltd. trading under the name Biobytes, operates as a company that uses AI to forecast and tackle sarcopenia, a condition associated with the loss of muscle mass as people age. In June 2026, Biobytes raised KRW 2.1 billion in pre-series A funding from new investors Be High Investment, Newborn Ventures, Korea Technology Finance Corporation. Other unspecified investors also participated in this round.

Biobytes provides biotechnology solutions to address critical needs in healthcare, agriculture, and environmental protection. The company's primary product methods to analyze genetic data and biopesticides derived from natural organisms to protect crops. These solutions are employed by research institutes, farmers, and environmental scientists throughout North America, Europe, and Asia.

The company plans to use the November 2024 funding to increase its manpower.

## Funding rounds

- Seed, Nov 20, 2024 — Gangwon Creative Economy Innovation Center
- Seed, Nov 12, 2024, $0.4M — Kingsley Ventures, Sopoong Ventures, Gangwon Creative Economy Innovation Center, CNT Tech

## Investors

- Kingsley Ventures (https://capitalatlas.ai/funds/kingsley-ventures) — Seed
- Sopoong Ventures (https://capitalatlas.ai/funds/sopoong-ventures) — Seed
- Gangwon Creative Economy Innovation Center (https://capitalatlas.ai/funds/gangwon-creative-economy-innovation-center) — Seed
- CNT Tech (https://capitalatlas.ai/funds/cnt-tech) — Seed